Afatinib for the treatment of non-small cell lung cancer

摘要: Introduction: Tyrosine kinase inhibitors (TKI) are currently the most effective therapy for patients with NSCLC and common activating mutations of EGFR. Afatinib, an irreversible EGFR, HER2, HER4 inhibitor, has recently been approved at dose 40 mg daily as front-line treatment advanced EGFR-activating mutations.Areas covered: The review analyzes pharmacodynamics, pharmacokinetics, safety, clinical efficacy afatinb in NSCLC. This TKI was initially investigated EGFR-unselected who progressed after TKIs, but subsequent observation its major activity against exon 19 mutant determined indication EGFR mutations. Several Phase I to III studies explored role afatinib different settings patients.Expert opinion: Afatinib showed a Currently, no statistically significant differences between afatinib, gefitinib, erlotinib have det...